Proprietary research, economic commentary, and investment perspectives from our experienced team of analysts and portfolio managers.
European equities remain attractive relative to US peers on a valuation basis. Earnings revisions are trending positive, supported by a resilient domestic economy and a stabilising manufacturing sector. We maintain an overweight stance with a focus on quality growth names.
With the ECB expected to hold rates through mid-2026, we see limited upside in sovereign bonds at current yields. Investment-grade credit spreads offer modest carry but limited compression potential. We favour shorter duration and selective high-yield exposure.
Global growth continues at a moderate pace with dispersion across regions. Geopolitical risks remain elevated, requiring careful portfolio positioning. Currency hedging remains an important component of our risk management toolkit in this environment.
In-depth analysis and thought leadership from our research desk.
AI-generated fake IDs are now sophisticated enough to pass first-generation verification checks. We break down how these synthetic documents are built, how modern verification systems catch them, and what regulators now expect from institutions onboarding investors at scale.
Read the Full Article →An analysis of emerging European technology companies that are challenging US incumbents in enterprise software, cybersecurity, and green technology. We identify five companies positioned to benefit from increasing European tech sovereignty.
Request Full Report →Our macro team examines the likely trajectory of ECB monetary policy through 2026 and its implications for equity valuations, credit spreads, and optimal portfolio positioning across different rate scenarios.
Request Full Report →A comprehensive review of how European companies are adapting to increasingly stringent carbon regulations. We assess which sectors and companies are best positioned to benefit from the energy transition and which face structural headwinds.
Request Full Report →Our annual analysis comparing active fund performance against passive benchmarks across European markets. We examine why certain market conditions favour active management and where the greatest opportunities for alpha generation exist.
Request Full Report →European pharma and medtech companies are trading at historically low valuations relative to their US peers despite strong pipeline innovation. We highlight opportunities in mid-cap biotech and medical device makers.
Request Full Report →Our comprehensive annual outlook covering macroeconomic forecasts, asset class views, sector preferences, and key risks for the year ahead. Includes specific portfolio positioning recommendations across all eight strategies.
Request Full Report →| Indicator | Current | 1 Month Ago | YTD Change | Our View |
|---|---|---|---|---|
| STOXX Europe 600 | 528.4 | 519.7 | +7.2% | Overweight |
| Euro Stoxx 50 | 5,142 | 5,038 | +8.1% | Overweight |
| EUR/USD | 1.0892 | 1.0815 | +1.4% | Neutral |
| German 10Y Bund | 2.35% | 2.42% | -18bps | Underweight |
| ECB Main Rate | 3.25% | 3.25% | Unchanged | Hold expected |
| EU IG Credit Spread | 108bps | 112bps | -14bps | Neutral |
Data as of 31 March 2026. Views represent ActiFund's current positioning and are subject to change.
Subscribe to our research updates and receive our latest insights directly in your inbox.